Juan Gómez-Rivas, MD, discusses barriers to PSMA-PET imaging and how disparities in access may affect prostate cancer staging and treatment planning.
Feature|Articles|September 1, 2025
FDA updates in urology: August 2025
Author(s)Hannah Clarke
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
A recap of the FDA submissions and regulatory decisions in urology from August 2025.
Advertisement
Advertisement
Welcome to Urology Times’® monthly FDA update! August ushered in several notable advancements, with a particular focus in prostate cancer. Specifically, key developments included regulatory approval of an artificial intelligence (AI)-based test, acceptance of an application for a new formulation of a prostate-specific membrane antigen (PSMA)-PET imaging agent, and approval of a new formulation of a drug for advanced prostate cancer.
Related to this article
The target enrollment goal has been reached in the phase 3 BiPASS study, evaluating PSMA-PET plus MRI for prostate cancer detection.
The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
Isaac Y. Kim, MD, PhD, MBA, joins to discuss the evolving data surrounding neoadjuvant therapy before radical prostatectomy in prostate cancer.
The study is assessing the safety and preliminary efficacy of CD28 co-stimulation in patients with mCRPC.
Lorelei A. Mucci, ScD, MPH, discusses the evolving evidence surrounding diet, physical activity, and other lifestyle factors in prostate cancer care.
Urologists compare ADT plus ARPI doublets and docetaxel triplets in mCSPC, weighing efficacy, safety, cognition, and cost against patient goals.
Martin Schoen, MD, PhD, explains how real-world evidence can help compare ARPIs and why study design and patient selection are critical to interpretation.
A randomized trial will test whether an app-guided, at-home PSA screening approach can improve prostate cancer screening among Black men.
Advertisement
Advertisement